- Home
- LEU vs CORT Comparison
LEU vs CORT Comparison
Compare LEU & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEU | CORT |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 1998 | 2001 |
Fundamental Metrics
Financial Performance| Metric | LEU | CORT |
|---|---|---|
| Price | $204.23 | $46.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $248.82 | $96.50 |
| AVG Volume (30 Days) | 707.1K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.90 | 0.82 |
| Revenue | $193,000,000.00 | ★ $761,407,000.00 |
| Revenue This Year | $3.76 | $26.08 |
| Revenue Next Year | $6.04 | $31.04 |
| P/E Ratio | ★ $51.94 | $53.61 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $60.52 | $28.66 |
| 52 Week High | $464.00 | $91.00 |
Technical Indicators
Market Signals| Indicator | LEU | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 72.72 |
| Support Level | $187.56 | $32.95 |
| Resistance Level | $219.85 | $47.06 |
| Average True Range (ATR) | 12.60 | 1.74 |
| MACD | 3.89 | 0.56 |
| Stochastic Oscillator | 86.38 | 99.12 |
Price Performance
Historical ComparisonAbout LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.